Your browser doesn't support javascript.
loading
Genetic regulation of OAS1 nonsense-mediated decay underlies association with risk of severe COVID-19
A Rouf Banday; Megan L Stanifer; Oscar Florez-Vargas; Olusegun O Onabajo; Muhammad A Zahoor; Brenen W Papenberg; Timothy J Ring; Chia-Han Lee; Evangelos Andreakos; Evgeny Arons; Greg Barsh; Leslie G Biesecker; David L Boyle; Andrea Burnett-Hartman; Mary Carrington; Euijin Chang; Pyoeng Gyun Choe; Rex L Chrisholm; Clifton Dalgard; Jeff Edberg; Nathan Erdmann; Heather S Feigelson; Gary S Firestein; Adam J Gehring; Michelle Ho; Steven Holland; Amy A Hutchinson; Hogune Im; Michael G Ison; Hong Bin Kim; Robert J Kreitman; Bruce R Korf; Lisa Mirabello; Jennifer A Pacheco; Michael J Peluso; Daniel J Rader; David T Redden; Marylyn D Ritchie; Brooke Rosenbloom; Hanaisa P Sant Anna; Sharon Savage; Eleni Siouti; Vasiliki Triantafyllia; Joselin M Vargas; Anurag Verma; Vibha Vij; Duane R Wesemann; Meredith Yeager; Xu Yu; Yu Zhang; Steeve Boulant; Stephen J Chanock; Jordan J Feld; Ludmila Prokunina-Olsson.
Afiliação
  • A Rouf Banday; National Cancer Institute, USA
  • Megan L Stanifer; University Hospital Heidelberg, Germany
  • Oscar Florez-Vargas; National Cancer Institute, USA
  • Olusegun O Onabajo; National Cancer Institute, USA
  • Muhammad A Zahoor; University of Toronto, Canada
  • Brenen W Papenberg; National Cancer Institute, USA
  • Timothy J Ring; National Cancer Institute, USA
  • Chia-Han Lee; National Cancer Institute, USA
  • Evangelos Andreakos; Biomedical Research Foundation of the Academy of Athens, Greece
  • Evgeny Arons; National Cancer Institute, USA
  • Greg Barsh; HudsonAlpha Institute for Biotechnology, USA
  • Leslie G Biesecker; National Human Genome Research Institute, USA
  • David L Boyle; University of California San Diego Health Sciences, USA
  • Andrea Burnett-Hartman; Kaiser Permanente Colorado, USA
  • Mary Carrington; National Cancer Institute, USA
  • Euijin Chang; Seoul National University College of Medicine, Korea
  • Pyoeng Gyun Choe; Seoul National University College of Medicine, Korea
  • Rex L Chrisholm; Northwestern University Feinberg School of Medicine, USA
  • Clifton Dalgard; Uniformed Services University of the Health Sciences, USA
  • Jeff Edberg; University of Alabama at Birmingham, USA
  • Nathan Erdmann; University of Alabama at Birmingham, USA
  • Heather S Feigelson; Kaiser Permanente Colorado, USA
  • Gary S Firestein; University of California San Diego Health Sciences, USA
  • Adam J Gehring; University of Toronto, Canada
  • Michelle Ho; National Cancer Institute, USA
  • Steven Holland; National Institute of Allergy and Infectious Diseases, USA
  • Amy A Hutchinson; Frederick National Laboratory for Cancer Research, USA
  • Hogune Im; Genome Opinion Inc, Korea
  • Michael G Ison; Northwestern University Feinberg School of Medicine, USA
  • Hong Bin Kim; Seoul National University College of Medicine, Korea
  • Robert J Kreitman; National Cancer Institute, USA
  • Bruce R Korf; University of Alabama at Birmingham, USA
  • Lisa Mirabello; National Cancer Institute, USA
  • Jennifer A Pacheco; Northwestern University Feinberg School of Medicine, USA
  • Michael J Peluso; University of California, USA
  • Daniel J Rader; University of Pennsylvania, USA
  • David T Redden; University of Alabama at Birmingham, USA
  • Marylyn D Ritchie; University of Pennsylvania, USA
  • Brooke Rosenbloom; National Human Genome Research Institute, USA
  • Hanaisa P Sant Anna; National Cancer Institute, USA
  • Sharon Savage; National Cancer Institute, USA
  • Eleni Siouti; Biomedical Research Foundation of the Academy of Athens, Greece
  • Vasiliki Triantafyllia; Biomedical Research Foundation of the Academy of Athens, Greece
  • Joselin M Vargas; National Cancer Institute, USA
  • Anurag Verma; University of Pennsylvania, USA
  • Vibha Vij; National Cancer Institute, USA
  • Duane R Wesemann; Brigham and Women Hospital, Harvard Medical School, USA
  • Meredith Yeager; Frederick National Laboratory for Cancer Research, USA
  • Xu Yu; Ragon Institute of MGH, MIT and Harvard, USA
  • Yu Zhang; National Institute of Allergy and Infectious Diseases, USA
  • Steeve Boulant; German Cancer Research Center (DKFZ), Germany
  • Stephen J Chanock; National Cancer Institute, USA
  • Jordan J Feld; University of Toronto, Canada
  • Ludmila Prokunina-Olsson; National Cancer Institute, USA
Preprint em Inglês | medRxiv | ID: ppmedrxiv-21260221
ABSTRACT
Genomic regions have been associated with COVID-19 susceptibility and outcomes, including the chr12q24.13 locus encoding antiviral proteins OAS1-3. Here, we report genetic, functional, and clinical insights into genetic associations within this locus. In Europeans, the risk of hospitalized vs. non-hospitalized COVID-19 was associated with a single 19Kb-haplotype comprised of 76 OAS1 variants included in a 95% credible set within a large genomic fragment introgressed from Neandertals. The risk haplotype was also associated with impaired spontaneous but not treatment-induced SARS-CoV-2 clearance in a clinical trial with pegIFN-{lambda}1. We demonstrate that two exonic variants, rs10774671 and rs1131454, affect splicing and nonsense-mediated decay of OAS1. We suggest that genetically-regulated loss of OAS1 expression contributes to impaired spontaneous clearance of SARS-CoV-2 and elevated risk of hospitalization for COVID-19. Our results provide the rationale for further clinical studies using interferons to compensate for impaired spontaneous SARS-CoV-2 clearance, particularly in carriers of the OAS1 risk haplotypes.
Licença
cc0
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Estudo prognóstico / Rct Idioma: Inglês Ano de publicação: 2021 Tipo de documento: Preprint
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Estudo prognóstico / Rct Idioma: Inglês Ano de publicação: 2021 Tipo de documento: Preprint
...